Valneva SE (EPA:VLA)
France · Delayed Price · Currency is EUR 2.888
-0.009 (-0.31%)
Sep 11, 2026, 5:35 PM CET
Valneva SE Market Cap
Valneva SE has a market cap or net worth of €547.7 million as of September 11, 2026. Its market cap has decreased by -16.25% in one year.
Market Cap
547.70M
Enterprise Value
636.41M
Revenue
142.94M
Ranking
n/a
PE Ratio
n/a
Stock Price
€2.89
ChartMarket Cap Chart
Since June 29, 2007, Valneva SE's market cap has increased from 99.08M to 547.70M, an increase of 452.80%. That is a compound annual growth rate of 9.31%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 11, 2026 | 547.70M | -14.73% |
| Dec 31, 2025 | 642.32M | 82.94% |
| Dec 31, 2024 | 351.10M | -46.40% |
| Dec 29, 2023 | 655.08M | -23.93% |
| Dec 30, 2022 | 861.12M | -66.55% |
| Dec 31, 2021 | 2.57B | 265.20% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Nanobiotix | 1.58B |
| Inventiva | 897.86M |
| MedinCell | 790.77M |
| DBV Technologies | 697.77M |
| Genfit | 615.30M |
| Valerio Therapeutics Société anonyme | 359.60M |
| Transgene | 241.29M |
| Cellectis | 199.19M |